

Resource Summary Report

Generated by PRECISE-TBI on Aug 3, 2026

Cureline

RRID:SCR_012546

Type: Tool

Proper Citation

Cureline (RRID:SCR_012546)

Resource Information

URL: <http://www.scienceexchange.com/facilities/cureline>

Proper Citation: Cureline (RRID:SCR_012546)

Description: Cureline, Inc., is a human biospecimen CRO specializing in human tissue research projects including study design, regulatory affairs, clinical network management, specimen collection and analysis, and complete logistics. We collaborate with major clinical centers in Europe, Asia, and the USA and maintain an extensive biorepository of human biospecimens in South San Francisco (CA, USA). Our expertise is biomarker research and diagnostic specimen collection for solid tumors, hematology, inflammation, cardiovascular conditions, sepsis/infectious diseases, and other indications. Our translational histology division is a CLIA, GLP laboratory that provides high-end tissue research services to the biomedical research community including IHC protocol development, clinical specimens processing and diagnostics, digital pathology, etc. Our managers have advanced degrees in medicine and/or science, and worked before in clinical trial operations, research laboratories, healthcare management and international business development areas.

Abbreviations: Cureline

Synonyms: Cureline Inc.

Resource Type: commercial organization, core facility, service resource, access service resource

Resource Name: Cureline

Resource ID: SCR_012546

Alternate IDs: SciEx_4563

Record Creation Time: 20220129T080310+0000

Record Last Update: 20260801T190438+0000

Ratings and Alerts

No rating or validation information has been found for Cureline.

No alerts have been found for Cureline.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Yudina A, et al. (2025) Clinical and analytical validation of a combined RNA and DNA exome assay across a large tumor cohort. *Communications medicine*, 5(1), 236.

Benjamin JS, et al. (2025) 23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa Activation. *Cancer research communications*, 5(3), 476.

Black JRM, et al. (2025) Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma. *Nature medicine*, 31(1), 70.

Jin C, et al. (2025) Molecular and genetic insights into human ovarian aging from single-nuclei multi-omics analyses. *Nature aging*, 5(2), 275.

Evans RT, et al. (2024) ASPYRE-Lung: validation of a simple, fast, robust and novel method for multi-variant genomic analysis of actionable NSCLC variants in FFPE tissue. *Frontiers in oncology*, 14, 1420162.

Sinha A, et al. (2024) Critical reagent considerations for immunogenicity assay development for bispecific biotherapeutic candidates. *Bioanalysis*, 16(15), 781.

Walsh J, et al. (2023) Analysis of ?-nerve growth factor and its precursor during human pregnancy by immunoaffinity-liquid chromatography tandem mass spectrometry. *Scientific reports*, 13(1), 9180.

Chen Z, et al. (2022) Phosphorylated MED1 links transcription recycling and cancer growth. *Nucleic acids research*, 50(8), 4450.

Tsuzuki H, et al. (2022) Anti-tumor effect of antibody drug conjugate ASP1235 targeting Fms-like tyrosine kinase 3 with venetoclax plus azacitidine in an acute myeloid leukemia xenograft mouse model. *Oncotarget*, 13, 1359.

Fong S, et al. (2022) Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A. *Nature medicine*, 28(4), 789.

Wang D, et al. (2022) Comparison of Two Illumina Whole Transcriptome RNA Sequencing Library Preparation Methods Using Human Cancer FFPE Specimens. *Technology in cancer research & treatment*, 21, 15330338221076304.

Assi HH, et al. (2021) Conditional PD-1/PD-L1 Probody Therapeutics Induce Comparable Antitumor Immunity but Reduced Systemic Toxicity Compared with Traditional Anti-PD-1/PD-L1 Agents. *Cancer immunology research*, 9(12), 1451.

Quan L, et al. (2020) Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation. *Journal of experimental & clinical cancer research : CR*, 39(1), 266.

Desbois M, et al. (2020) Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. *Nature communications*, 11(1), 5583.

Peluso MO, et al. (2020) The Fully human anti-CD47 antibody SRF231 exerts dual-mechanism antitumor activity via engagement of the activating receptor CD32a. *Journal for immunotherapy of cancer*, 8(1).

Van Laar R, et al. (2018) Development and validation of a plasma-based melanoma biomarker suitable for clinical use. *British journal of cancer*, 118(6), 857.